APOA1 and metabolic dysfunction-associated steatotic liver disease: In this study, NAFLD rats treated with HXQYF for 18 weeks showed a higher level of serum APOA1 and lower ApoB, which were coincidence with the HDL-C and LDL-C levels in rats treated with HXQYF.